Fine, Kaplan and Black, R.P.C., Announce a Class Action Settlement If You Paid or Reimbursed for Certain Prescription Generic Drugs in the United States Between May 1, 2009 and December 31, 2019

USA - English

• USA - Traditional Chinese
• USA - Chinese
• USA - español

PHILADELPHIA, Oct. 3, 2025 /PRNewswire/ --

LEGAL NOTICE

If You Paid or Reimbursed for Certain PRESCRIPTION GENERIC DRUGS in the United States between May 1, 2009 and December 31, 2019, You Could Get a Payment from a Class Action Settlement.

A federal court authorized this Notice.
This is not a solicitation from a lawyer.

1-877-316-0171
www.GenericDrugsEndPayerSettlement.com 

Your legal rights might be affected by a new $200 million Settlement with Sun Pharmaceutical Industries, Inc. ("Sun") and Taro Pharmaceuticals U.S.A., Inc. ("Taro") ("Sun/Taro" refers to both entities) in a class action lawsuit (In re Generic Pharmaceuticals Antitrust Litigation, No. 16-MD-2724 (E.D. Pa.)). The lawsuit claims generic manufacturers violated federal and state antitrust laws, consumer protection statutes, and common law, causing End-Payers – including Consumers and Third-Party Payers ("TPPs") (e.g., entities such as insurers or employers with self-funded prescription drug plans) – to pay more than they should have for certain generic drugs ("Named Generic Drugs"). Sun/Taro denies liability. The lawsuit remains ongoing against the Non-Settling Defendants.

 Am I a Settlement Class Member? This lawsuit was brought by End-Payers for Named Generic Drugs ("EPPs"), and the court has preliminarily certified an EPP Sun/Taro Settlement Class that consists of TPPs and Consumers. You may be an EPP Sun/Taro Settlement Class Member if you are a TPP or Consumer that indirectly purchased, paid for, and/or provided reimbursement for some or all of the purchase price for one or more of the Named Generic Drugs, for personal use by yourself or your members, and other than for resale, in the United States (except Indiana and Ohio) and in some United States territories, at any time during the period from May 1, 2009 through December 31, 2019. Certain kinds of entities are excluded from the EPP Sun/Taro Settlement Class. A more detailed notice that includes the full class description and who is or is not included; the list of Named Generic Drugs; the complete list of Defendants; and the Settlement Agreement are available at www.GenericDrugsEndPayerSettlement.com (the "EPP Settlement Website").

What does the Settlement provide? Under the proposed Settlement, Sun/Taro has paid $200 million into a settlement fund. The settlement fund may be reduced under certain circumstances, as explained in the Settlement Agreement. It will be used to pay eligible EPP Sun/Taro Settlement Class Members, after deductions for settlement notice and administration costs (up to $750,000); and, subject to Court approval, attorneys' fees of up to one-third of the fund plus interest, unreimbursed litigation expenses, plus an additional amount for future expenses in further litigation against the remaining Defendants (up to $4,000,000 for past and future expenses), and service awards to the Settlement Class Representatives (up to $500,000 total). Settlement Class Counsel will post their request for fees, expenses, and service awards on the EPP Settlement Website. Sun/Taro also agreed to cooperate with EPPs in providing information related to EPPs' litigation against the Non-Settling Defendants.

How do I get a payment? Money will be distributed if and after the Court approves the Settlement. The amount and the timing of payment will be based on a Plan of Allocation that must be approved by the Court. EPPs' proposed Plan of Allocation is posted on the EPP Settlement Website. The claims process will open at a later date. To receive Settlement-related updates, including when claim forms are available, you should register on the EPP Settlement Website or call the toll-free number below.

If I am an EPP Sun/Taro Settlement Class Member, what are my options? If you do nothing, you will remain an EPP Sun/Taro Settlement Class Member, be eligible to participate in the Settlement, and be legally bound by the Court's rulings on the Settlement and the claims against Sun/Taro, and you will not be able to pursue your claims against Sun/Taro. If you do not want to be legally bound by the Settlement, or if you want to keep your right to sue Sun/Taro yourself, you must exclude yourself. If you elect to remain in the Settlement Class but object to some or all of the Settlement, the proposed Plan of Allocation, the request for attorneys' fees, expenses, or the proposed service awards, you may object. Details on how to request exclusion or object are on the EPP Settlement Website. Any exclusion requests or objections must be submitted by December 2, 2025. The Court will hold a Fairness Hearing on January 15, 2026 at 11:00 a.m. to decide whether to approve the Settlement, the Plan of Allocation, and any request for attorneys' fees, expenses, or service awards. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court, and you may (but are not required to) hire your own attorney to appear in court for you at your own expense. The Court may change deadlines or the date and time of the hearing. Check the EPP Settlement Website for updates.

In re Generic Pharmaceuticals End-Payer Antitrust Litigation
c/o A.B. Data, Ltd.
P.O. Box 173118
Milwaukee, WI 53217

For more information: Call 1-877-316-0171 or visit www.GenericDrugsEndPayerSettlement.com. 

SOURCE Fine, Kaplan, and Black, R.P.C.